Monday, November 29, 2010
Sunday, November 28, 2010
Saturday, November 27, 2010
As per the claim by the researchers, the complexes are better than the second line drugs (we know already about drug resistant tubercular species and tuberculosis is being considered as re-emerging disease due to the increase in the number of people with HIV and other viruses that attack the immune system, as well as to the increasing consumption of immunosuppressive and recreational drugs). Another advantage of the iron compounds is that they show low toxicity in mammal cells, as demonstrated by the experiments performed with mice cells.
"That is why these compounds are useful as hospital disinfectants or therapeutic agents," the Uruguayan researchers highlight, albeit recalling that, at present, they in vitro trials "and the line of research remains open to learn more about how they act."
Thursday, November 25, 2010
Tuesday, November 23, 2010
We know that. Tranilast (structure, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. It has been also reported that it reduces (in-vitro) collagen synthesis in fibroblasts, inhibits the growth of neurofibroma cells and inhibits ( in-vitro) the production of interleukin-6 in endothelial cells.
Now researchers from St. Michael's Hospital, Canada reports that the drug to stop the spread of breast cancer cells traditionally resistant to chemotherapy.
Researchers grew breast cancer stem cells, which give rise to other cancer cells, in culture. The cells were injected into two groups of mice, including one group, which was also treated with tranilast. Dr. Prud'homme and his colleagues found the drug reduced growth of the primary cancerous tumour by 50 per cent and prevented the spread of the cancer to the lungs. Researchers also identified a molecule in the cancer cell that binds to tranilast and appears to be responsible for this anti-cancer effect.
As per the researchers 'Tranilast' binds to a molecule known as the aryl hydrocarbon receptor (AHR), which regulates cell growth and some aspects of immunity. This makes the drug beneficial in treating allergies, inflammatory diseases and cancer.
"For the first time, we were able to show that tranilast shows promise for breast cancer treatment in levels commonly well-tolerated by patients who use the drug for other medical conditions," Dr. Prud'homme said. "These results are very encouraging and we are expanding our studies. Further studies are necessary to determine if the drug is effective against different types of breast and other cancers, and its interaction with anti-cancer drugs.........
Tuesday, November 16, 2010
Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting
Tuesday, November 9, 2010
Sunday, November 7, 2010
We knew that, Dabigatran (see structure, Pradaxa in Europe and USA, Pradax in Canada) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner since it does not require prothrombin time monitoring while offering similar results in terms of efficacy. It was developed by the pharmaceutical company Boehringer Ingelheim. Though it was approved in Europe in 2008, now FDA has approved the drug in October 2010 for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).
Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. The safety and efficacy of Pradaxa were studied in a clinical trial comparing Pradaxa with the anticoagulant warfarin. In the trial, patients taking Pradaxa had fewer strokes than those who took warfarin.
"Unlike warfarin, which requires patients to undergo periodic monitoring with blood tests, such monitoring is not necessary for Pradaxa," Dr. Norman Stockbridge(director of the Division of Cardiovascular and Renal Products in the FDA's ) says.
Pradaxa, manufactured by Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., will be available in 75 milligram and 150 milligram capsules....